Latest Pharmaceutical Regulatory Compliance News

Page 1 of 1

Mayne Pharma Withdraws NEXTSTELLIS® Presentation After FDA Letter, Sales Unaffected

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Victor Sage

14 May 2025

Browse the archive

Full archive

Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026